<DOC>
	<DOCNO>NCT02249221</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity GC3106 single intramuscular administration Korean healthy adult .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity GC3106 ( Quadrivalent Cell-culture Based Influenza Vaccine )</brief_title>
	<detailed_description>This study first human trial GC3106 design adaptive Phase I/IIa ensure participant protection . Part A open-label single arm study 9 healthy volunteer . Data Safety Monitoring Board ( DSMB ) review solicited/unsolicited adverse event conditionally toxicity Grade 3 4 report 7 day vaccination first 9 healthy volunteer . Part B randomize ( 2:1 ) , double-blind , active control study total 75 volunteer participate part . Adverse event assessment do accord 'Toxicity Grading Scale Healthy Adult Adolescent Volunteers Enrolled Preventive Vaccine Clinical Trials ' .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Given write informed consent Healthy Korean adult ( age : 19 65 ) Korean adult agree 21 day follow vaccination good compliance study procedure Those able comply requirement study Inability written/verbal communication Subjects participate interventional study within 30 day Alcohol drug abuse within 6 month Heavy drinker subject agree stop drinking 3 day vaccination 3 day vaccination Who get treatment psychotropic drug narcotic analgesic drug within 6 month enrollment Hypersensitivity drug active ingredient Disorders immune function History GuillainBarré syndrome Disease/medications likely cause severe bleed Active infection experience fever ( &gt; 38.0 ℃ ) within 72 hour follow vaccination Oral temperature &gt; 38.0 ℃ vaccination day Erythema , tattoo , injury shoulder ( vaccination site ) Influenza vaccination within 6months Any vaccination within 30 day Concomitant medications/therapy immunosuppressant immune modify drug , systemic corticosteroid , immunoglobulin , blood blood derive product , anticancer chemotherapy radiation therapy within3 month Pregnant breastfeed woman Clinically significant underlying disease medical history investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Vaccination</keyword>
	<keyword>cell-culture base influenza vaccine</keyword>
	<keyword>cell culture derive influenza vaccine</keyword>
	<keyword>CCIV</keyword>
</DOC>